Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Bayer
Woman and Man Max 99 years
Bayer B.V. (The Netherlands)
Update Il y a 4 ans
A double blind placebo controlled study on the effect of cerivastatin on the process of atherosclerosis in non-insulin dependent diabetes mellitus
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Bayer
Update Il y a 4 ans
Étude 19131-FORT-2 : étude de phase 1b-2 évaluant l’efficacité du rogaratinib en association avec de l’atézolizumab en traitement de première ligne chez des patients ayants un cancer urothélial métastatique positif au FGFR et non éligible à une chimiothérapie de cisplatine.
Le carcinome urothélial représente plus de 90% des cancers de la vessie. Il peut subvenir dans n’importe quelle partie de l’appareil urinaire (le bassinet du rein, l’uretère, la vessie ou l’urètre). C...
Country
France
organs
Rein
,
Vessie
,
Appareil urinaire - autres
Specialty
Immunothérapie - Vaccinothérapie
,
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 4 ans
An open-label, uncontrolled and non-blinded study to assess different doses of a new drug (Bay 63-2521), given orally as multiple ascending doses, to evaluate if it is safe and can help to improve the well-being of patients with interstitial lung disease associated pulmonary hypertension by lowering the pulmonary artery blood pressure
Main objective of the trial is to investigate the safety and tolerability of a 12-week treatment with BAY 63-2521 of patients with pulmonary hypertension due to intestinal lung disease (ILD idiopathic...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
Safety and Efficacy of Oral BAY 85-8501 in Patients with inflammation of the tubes in the lungs
To assess the safety and tolerability of 28 day oral administration of BAY 85-8501 versus placebo in subjects with non-CF Bronchiectasis (BE)
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
Placebo controlled, randomized, double-blind, multi-center, multinational Phase IIb study to investigate the efficacy and tolerability of BAY 58-2667 given intravenously in patients with decompensated chronic congestive heart failure
Primary objective of the study is to investigate the safety and efficacy of a titration phase (8 hours) and a maintenance phase (maximum 40 hours) of intravenous BAY 58-2667 in patients with acute dec...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
This clinical study evaluates the efficacy and safety of regorafenib in patients with advanced liver cancer who have progressed on sorafenib treatment
The objective of this study is to evaluate efficacy and safety of regorafenib in patients with HCC who have progressed after sorafenib
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
Phase IIa Efficacy and Safety Trial of capadenoson in Patients with Chronic Stable Angina
The main objective of this study is to demonstrate that chronic administration of BAY 68-4986 for 28 days at doses of 1 mg, 2 mg and 4 mg, is efficacious in a patient population with chronic stable an...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer Schering Pharma AG
Update Il y a 4 ans
Phase I/II study to investigate the safety, tolerability, efficacy and pharmacokinetics of ZK 219477 in combination with cisplatin as first-line therapy in chemotherapy-naive patients with extensive-disease (ED) stage small-cell lung cancer (SCLC)
Phase I-part: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of ZK 219477 in combination with cisplatin To investigate the safety and tolerability of ZK 219477 in co...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
A randomized, double-blind, placebo-controlled, multi-center, parallel group study to assess the efficacy of vardenafil in the treatment of symtomatic Benign Prostatic Hyperplasia
To assess the efficacy, tolerability and safety of vardenafil (10 mg BID) versus placebo in the two month treatment of men with symptomatic BPH.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
Study to investigate the effect of the A1 agonist capadenoson on ventricular HR in patients with persistent or permanent atrial fibrillation by administration of capadenoson in a dose of 4 mg once daily for five days
Primary objective of the study is to investigate the effect of capadenoson (BAY 68-4986) 4 mg granulate once daily for 5 days on rate control in patients with atrial fibrillation in comparison to base...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
3
4
5
6
7
8
9
10
11
12
Next